US · Healthcare · Drug Manufacturers - General
EPS came in at 0.80 against a street estimate of 0.85 — a miss of 5.9%.
Analysts rate Organon & Co a hold (2 buy, 3 hold, 2 sell out of 7) with an average price target of $11.25.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.08% |
| Vanguard Portfolio Management, LLC | 8.32% |
| Pentwater Capital Management LP | 6.89% |
| Vanguard Capital Management, LLC | 4.47% |
| State Street Corp | 3.79% |
| Kahn Brothers & CO Inc /DE/ | 2.11% |
| Geode Capital Management, LLC | 1.81% |
| Private Management Group Inc | 1.67% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ORGANON & CO. - FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Six-month revenue: $3,018 million (down from $3,107 million in | 2026-07-31 |
| Reg FD disclosure · Q3 2026 ORGANON & CO. - FORM 8-K SUMMARY HEADLINE NUMBERS • Reporting Period: Quarter ended June 30, 2026 • Filing Date: July 31, 2026 • Company: Organon & | 2026-07-31 |
| Shareholder vote results · Q3 2026 ORGANON & CO. - 8-K SUMMARY HEADLINE NUMBERS • Merger Approval Vote Date: July 23, 2026 • Record Date Shares Outstanding: 262,609,433 shares of Comm | 2026-07-23 |
| Company announcement · Q3 2026 ORGANON & CO. - 8-K FILING SUMMARY Filed: July 17, 2026 --- HEADLINE NUMBERS • Merger Price & Share Count: Sun Pharmaceutical acquiring Organon at | 2026-07-17 |
| Board / officer change · Q2 2026 ORGANON & CO. - FORM 8-K SUMMARY (June 9, 2026) BUSINESS & SEGMENT HIGHLIGHTS • Company held 2026 Annual Meeting on June 9, 2026 with stockholder pa | 2026-06-11 |
| Quarterly report · Q1 2026 ORGANON & CO. (OGN) – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $1,460 million (down from $1,513 million in Q1 2025, a 3.5% decline) | 2026-05-04 |
| Proxy statement · Q2 2026 ORGANON & CO. PROXY STATEMENT SUMMARY FOR RETAIL INVESTORS --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of 10 director nominees for o | 2026-04-24 |
| Annual report FY2025 ORGANON & CO. - 2025 10-K SUMMARY HEADLINE NUMBERS • Total 2025 revenues: $6.2 billion • Women's Health revenues: $1.752 billion (28% of total; 49% | 2026-02-24 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.02 / share ex-date Aug 14, 2026 · pay Sep 10, 2026 | 2026-08-14 |
| Dividend | $0.02 / share ex-date May 11, 2026 · pay Jun 11, 2026 | 2026-05-11 |
| Dividend | $0.02 / share ex-date Feb 23, 2026 · pay Mar 12, 2026 | 2026-02-23 |
| Dividend | $0.02 / share ex-date Nov 20, 2025 · pay Dec 11, 2025 | 2025-11-20 |
| Dividend | $0.02 / share ex-date Aug 15, 2025 · pay Sep 11, 2025 | 2025-08-15 |
| Announcement | Date |
|---|---|
| Special meeting held to vote on merger proposal Organon Co. held a special stockholder meeting on July 23, 2026, to vote on its merger with Sun Pharmaceutical Industries Limited. Shareholders overwhelmingly approved the merger agreement, | 2026-07-23 |
| Merger agreement with Sun Pharmaceutical Holdings USA disclosed Organon Co. (OGN) is being acquired by Sun Pharmaceutical in a merger agreement signed April 26, 2026. A shareholder lawsuit was filed July 6, 2026, alleging the proxy statement contained ma | 2026-07-17 |
| Entry into merger agreement with Parent and Merger Sub Organon announced on April 26, 2026, that it has entered into a merger agreement with a parent company and merger subsidiary. Key personnel changes were formalized: CEO Morrissey received a | 2026-04-27 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Organon & Co — free to start.
Google PlayApp StoreData updated 2026-09-18.